Used primarily as a second-line antituberculosis agent, especially in cases of resistance to first-line drugs like isoniazid and rifampin. It is effective against Mycobacterium tuberculosis by inhibiting folate synthesis, which is essential for bacterial growth. Due to its role in reducing drug resistance development, it is often used in combination therapy for multidrug-resistant tuberculosis (MDR-TB). The compound is also investigated for its anti-inflammatory properties and has been explored in the treatment of inflammatory bowel diseases such as ulcerative colitis, similar to other salicylates. Its use is limited by gastrointestinal side effects, but it remains important in specific clinical settings where alternative treatments are not feasible.